DOCSLIB.ORG

Utility of Whole Blood Thiamine Pyrophosphate Evaluation in TPK1-Related Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Utility of Whole Blood Thiamine Pyrophosphate Evaluation in TPK1-Related Diseases Journal of Clinical Medicine Case Report Utility of Whole Blood Thiamine Pyrophosphate Evaluation in TPK1-Related Diseases Enrico Bugiardini 1,2 , Simon Pope 3, René G. Feichtinger 4 , Olivia V. Poole 1,2, Alan M. Pittman 2, Cathy E. Woodward 5, Simon Heales 3, Rosaline Quinlivan 1,2,6, Henry Houlden 1,2, Johannes A. Mayr 4, Michael G. Hanna 1,2 and Robert D.S. Pitceathly 1,2,* 1 MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK 2 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK 3 Neurometabolic Unit, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK 4 Department of Pediatrics, University Hospital Salzburg, Paracelsus Medical University,5020 Salzburg, Austria 5 Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK 6 Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, London WC1N 3JH, UK * Correspondence: [email protected]; Tel.: +44-(0)2031087527 Received: 30 May 2019; Accepted: 3 July 2019; Published: 8 July 2019 Abstract: TPK1 mutations are a rare, but potentially treatable, cause of thiamine deficiency. Diagnosis is challenging given the phenotypic overlap that exists with other metabolic and neurological disorders. We report a case of TPK1-related disease presenting with Leigh-like syndrome and review the diagnostic utility of thiamine pyrophosphate (TPP) blood measurement. The proband, a 35-year-old male, presented at four months of age with recurrent episodes of post-infectious encephalopathy. He subsequently developed epilepsy, learning difficulties, sensorineural hearing loss, spasticity, and dysphagia. There was a positive family history for Leigh syndrome in an older brother. Plasma lactate was elevated (3.51 mmol/L) and brain MRI showed bilateral basal ganglia hyperintensities, indicative of Leigh syndrome. Histochemical and spectrophotometric analysis of mitochondrial respiratory chain complexes I, II+III, and IV was normal. Genetic analysis of muscle mitochondrial DNA was negative. Whole exome sequencing of the proband confirmed compound heterozygous variants in TPK1: c. 426G>C (p. Leu142Phe) and c. 258+1G>A (p.?). Blood TPP levels were reduced, providing functional evidence for the deleterious effects of the variants. We highlight the clinical and bioinformatics challenges to diagnosing rare genetic disorders and the continued utility of biochemical analyses, despite major advances in DNA sequencing technology, when investigating novel, potentially disease-causing, genetic variants. Blood TPP measurement represents a fast and cost-effective diagnostic tool in TPK1-related diseases. Keywords: mitochondrial diseases; TPK1; thiamine pyrophosphate; Leigh syndrome; thiamine deficiency 1. Introduction Genetic disorders of thiamine transport and metabolism are a rare but treatable cause of thiamine deficiency that usually present during childhood [1]. Four genetic defects are reported; three present with a predominantly neurological phenotype (SLC19A3, SLC25A19 and TPK1) and one with multisystem disease (SLC19A2), including megaloblastic anaemia, thrombocytopenia, diabetes, and hearing loss. Thiamine pyrophosphokinase 1 (hTPK1, EC2.7.6.2), encoded by TPK1, converts free thiamine to active thiamine pyrophosphate (TPP). Early recognition is therefore crucial given the potential benefits of thiamine supplementation. However, diagnosis of TPK1-related diseases is often J. Clin. Med. 2019, 8, 991; doi:10.3390/jcm8070991 www.mdpi.com/journal/jcm J.J. Clin.Clin. Med. 2019,, 8,, 991x FOR PEER REVIEW 22 of 99 delayed because of the clinical overlap with other metabolic diseases, including Leigh syndrome. delayedConsequently, because patients of the often clinical undergo overlap numerous with other investigations, metabolic diseases, including including muscle and Leigh skin syndrome. biopsies, Consequently,prior to receiving patients a molecular often undergo diagnosis. numerous Here, investigations,we describe a including case of TPK1 muscle-related and skin disease biopsies, that priorhighlights to receiving the potential a molecular applications diagnosis. of whole Here, blood we TPP describe measurement a case offorTPK1 diagnosis-related and disease subsequent that highlightsbiochemical the monitoring potential applications following thiamine of whole supplementation. blood TPP measurement for diagnosis and subsequent biochemical monitoring following thiamine supplementation. 2. Case Presentation 2. Case Presentation The proband, the fourth child of healthy unrelated parents, was an uncomplicated pregnancy and Thedelivery proband, and thereached fourth all child early of healthymotor mileston unrelatedes parents,without was delays. an uncomplicated An older brother pregnancy had been and deliverydiagnosed and with reached Leigh all syndrome early motor in milestonesthe early childh withoutood, delays. while Antwo older older brother siblings had were been healthy. diagnosed He withpresented Leigh with syndrome a post-viral in the encephalopathy early childhood, aged while four two months older siblings following were varicella-zoster healthy. He presented infection withand at a post-viralnine months encephalopathy sensorineural agedhearing four loss months was detected. following He varicella-zoster subsequently experienced infection and recurrent at nine monthsepisodes sensorineural of encephalopathy hearing associated loss was detected.with interc Heurrent subsequently infection experiencedand was diagnosed recurrent with episodes learning of encephalopathydifficulties and seizures. associated At with 22 ye intercurrentars he was infectionevaluated and in wasa specialist diagnosed mitochondrial with learning clinic. diffi Atculties this andtime, seizures. he required At 22 yearsfulltime he wasuse evaluatedof a wheelchair in a specialist and, despite mitochondrial improved clinic. seizure At this control time, he with required dual fulltimeanticonvulsant use of atherapy, wheelchair continued and, despite to experience improved seizure daily controlepisodes with of dualfocal anticonvulsant impaired awareness. therapy, continuedNeurological to examination experience daily revealed episodes optic disc of focal atroph impairedy and sensorineural awareness. hearing Neurological loss. In examination limbs, there revealedwas a spastic optic increase disc atrophy in tone, and hyper-reflexia, sensorineural and hearing bilateral loss. extensor In limbs, plantar there wasresponses. a spastic Laboratory increase intests, tone, including hyper-reflexia, CPK, fasting and bilateral acylcarnitine extensor profile, plantar and responses. very long Laboratory chain fatty tests, acids, including were normal. CPK, fastingPlasma acylcarnitinelactate was elevated profile, (3.51 and verymmol/L, long reference chain fatty range acids, 0.5–2.22 were mmol/L). normal. PlasmaBrain MRI lactate revealed was elevatedbilateral, (3.51symmetrical mmol/L, T2 reference hyperintensities range 0.5–2.22 in the mmol corpus/L). striatum Brain MRI and revealed severe bilateral,cerebellar symmetrical and moderate T2 hyperintensitiesbrainstem volume in loss, the corpus without striatum signal abnormalities and severe cerebellar (Figure and1). The moderate cervical brainstem spinal cord volume displayed loss, withoutnormal signalimaging abnormalities appearances. (Figure 1). The cervical spinal cord displayed normal imaging appearances. Figure 1. Brain MRI. (A) Axial image demonstrates bilateral, symmetrical T2-weighted high signal intensitiesFigure 1. Brain within MRI. the corpus(A) Axial striatum image (arrows). demonstrates (B) Sagittal bilateral, image symmetrical shows cerebellar T2-weighted atrophy high (asterisk). signal intensities within the corpus striatum (arrows). (B) Sagittal image shows cerebellar atrophy (asterisk). Pyruvate dehydrogenase complex (PDC) activity in cultured fibroblasts, and histological, histochemical,Pyruvate dehydrogenase and mitochondrial complex respiratory (PDC) chainactivity enzyme in cultured analyses fibroblasts, of skeletal and muscle histological, tissue, washistochemical, normal. Sanger and mitochondrial sequencing ofrespiratory the entire chain mitochondrial enzyme analyses genome of andskeletal molecular muscle analysis tissue, was for largenormal. scale Sanger mitochondrial sequencing DNA of the rearrangements entire mitochondr usingial longgenome range and PCR molecular were negative. analysis Wholefor large exome scale sequencingmitochondrial was DNA performed rearrangements using the using proband’s long genomicrange PCR DNA were extracted negative. from Whole peripheral exome sequencing leukocytes (AppendixA). Variants with a minor allele frequency (MAF) of 0.01 reported in gnomAD [2] and was performed using the proband’s genomic DNA extracted from≥ peripheral leukocytes (Appendix 1000A). Variants Genomes with databases, a minor andallele synonymous frequency (MAF) and deep of ≥0.01 intronic reported variants, in gnomAD were excluded. [2] and 1000 Recessive Genomes and X-linkeddatabases, inheritance and synonymous patterns were and prioritiseddeep intronic (Supplementary variants, were Figure excluded. S1). First, Recessive a list of genes and encodingX-linked mitochondrial-localizedinheritance patterns were proteins prioritised (n = 1158, (Supplementary Mitocarta) [3] was Figure analysed. S1). First, A variant a list in ofNDUFA1 genes (c.94Gencoding>C; p.Gly32Arg),mitochondrial-localized previously proteins
Load more

Recommended publications
  • Viewed Under 23 (B) Or 203 (C) fi M M Male Cko Mice, and Largely Unaffected Magni Cation; Scale Bars, 500 M (B) and 50 M (C)
    BRIEF COMMUNICATION www.jasn.org Renal Fanconi Syndrome and Hypophosphatemic Rickets in the Absence of Xenotropic and Polytropic Retroviral Receptor in the Nephron Camille Ansermet,* Matthias B. Moor,* Gabriel Centeno,* Muriel Auberson,* † † ‡ Dorothy Zhang Hu, Roland Baron, Svetlana Nikolaeva,* Barbara Haenzi,* | Natalya Katanaeva,* Ivan Gautschi,* Vladimir Katanaev,*§ Samuel Rotman, Robert Koesters,¶ †† Laurent Schild,* Sylvain Pradervand,** Olivier Bonny,* and Dmitri Firsov* BRIEF COMMUNICATION *Department of Pharmacology and Toxicology and **Genomic Technologies Facility, University of Lausanne, Lausanne, Switzerland; †Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts; ‡Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russia; §School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia; |Services of Pathology and ††Nephrology, Department of Medicine, University Hospital of Lausanne, Lausanne, Switzerland; and ¶Université Pierre et Marie Curie, Paris, France ABSTRACT Tight control of extracellular and intracellular inorganic phosphate (Pi) levels is crit- leaves.4 Most recently, Legati et al. have ical to most biochemical and physiologic processes. Urinary Pi is freely filtered at the shown an association between genetic kidney glomerulus and is reabsorbed in the renal tubule by the action of the apical polymorphisms in Xpr1 and primary fa- sodium-dependent phosphate transporters, NaPi-IIa/NaPi-IIc/Pit2. However, the milial brain calcification disorder.5 How- molecular identity of the protein(s) participating in the basolateral Pi efflux remains ever, the role of XPR1 in the maintenance unknown. Evidence has suggested that xenotropic and polytropic retroviral recep- of Pi homeostasis remains unknown. Here, tor 1 (XPR1) might be involved in this process. Here, we show that conditional in- we addressed this issue in mice deficient for activation of Xpr1 in the renal tubule in mice resulted in impaired renal Pi Xpr1 in the nephron.
    [Show full text]
  • A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(E) and Its Derivatives
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Advance Access Publication 1 February 2006 eCAM 2006;3(1)49–59provided by PubMed Central doi:10.1093/ecam/nek009 Review A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(e) and Its Derivatives Derrick Lonsdale Preventive Medicine Group, Derrick Lonsdale, 24700 Center Ridge Road, Westlake, OH 44145, USA Thiamin(e), also known as vitamin B1, is now known to play a fundamental role in energy metabolism. Its discovery followed from the original early research on the ‘anti-beriberi factor’ found in rice polish- ings. After its synthesis in 1936, it led to many years of research to find its action in treating beriberi, a lethal scourge known for thousands of years, particularly in cultures dependent on rice as a staple. This paper refers to the previously described symptomatology of beriberi, emphasizing that it differs from that in pure, experimentally induced thiamine deficiency in human subjects. Emphasis is placed on some of the more unusual manifestations of thiamine deficiency and its potential role in modern nutri- tion. Its biochemistry and pathophysiology are discussed and some of the less common conditions asso- ciated with thiamine deficiency are reviewed. An understanding of the role of thiamine in modern nutrition is crucial in the rapidly advancing knowledge applicable to Complementary Alternative Medi- cine. References are given that provide insight into the use of this vitamin in clinical conditions that are not usually associated with nutritional deficiency. The role of allithiamine and its synthetic derivatives is discussed.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • Takahiro NISHIMUNEI * and Ryoji HAYASHI2,** Summary Thiamin
    J. Nutr. Sci. Vitaminol., 33, 113-127, 1987 Hydrolysis and Synthesis of Thiamin Triphosphate in Bacteria Takahiro NISHIMUNEI* and Ryoji HAYASHI2,** Osaka Prefectural Institute of Public Health, Nakamichi, Higashinari-ku, Osaka 537, Japan (Received September 25, 1986) Summary Thiamin triphosphate (ThTP) in early stationary phase cells of Escherichia coli grown in nutrient broth with 0.1% yeast extract was fo und to constitute approximately 5-7% of cellular thiamin diphosphate (ThDP) or around 5nmol/g cell. Nearly the same level of. ThTP was obtained in a Bacillus strain. When E. coli was loaded with an excess of ThTP or ThDP, cellular ThTP was found to be controlled in the course of the long term to maintain its ratio to the amount of cellular ThDP. The ThTP vs. ThDP ratio in E. coli cells after short-term ThDP uptake was fo und to be a function of the cellular growth phase. The ratio in early exponential phase E. coli cells was found to be approximately 4% and it became lower (less than 3%) when cell growth proceeded to the late exponential stage. Two phosphatases specific for ThTP (ThTPase) among thiamin phosphates were detected in E. coli. One required Mgt2+and was fo und mainly in the soluble fraction, while the other was Mgt+ independent and originated from the membrane. The two ThTPases were similar to their rat tissue counterparts. Key Words thiamin triphosphate, thiamin triphosphatase, thiamin di phosphate kinase, thiamin pyrophosphate, thiamin, E. coli Recently, data on thiamin triphosphate (ThTP) in the tissues of higher organisms as determined by high performance liquid chromatography (HPLC) have been accumulating (1, 2).
    [Show full text]
  • Thiamine Phosphokinase Deficiency and Mutation in TPK1 Presenting As
    Clinica Chimica Acta 499 (2019) 13–15 Contents lists available at ScienceDirect Clinica Chimica Acta journal homepage: www.elsevier.com/locate/cca Thiamine phosphokinase deficiency and mutation in TPK1 presenting as biotin responsive basal ganglia disease T ⁎ William L. Nyhan , Karen McGowan, Bruce A. Barshop Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, CA, USA ARTICLE INFO ABSTRACT Keywords: The product of thiamine phosphokinase is the cofactor for many enzymes, including the dehydrogenases of TPK1 pyruvate, 2-ketoglutarate and branched chain ketoacids. Its deficiency has recently been described in a small Basal Ganglia number of patients, some of whom had a Leigh syndrome phenotype. The patient who also had a Leigh phe- Thiamine phosphokinase notype was initially found to have a low concentration of biotin in plasma and massive urinary excretion of biotin. Despite treatment with biotin and thiamine, her disease was progressive. Mutations c.311delG and c.426G > C were found in the TPK1 gene. 1. Introduction followed by decreased consciousness, increased tone and posturing. Concentration of pyruvate in the plasma was normal. Lactate ranged Thiamine phosphokinase (TPK) (EC2.7.6.2) catalyzes the transfer of from 0.2 to 0.4. mmol/L. A diagnosis of Leigh disease was made, and a pyrophosphate moiety from ATP to thiamine to form thiaminepyr- treatment was initiated with thiamine [4]. ophosphate (TPP). This compound is the cofactor for a variety of en- At 10 years of age, she had dystonic quadriparesis and was wheel- zymes, particularly pyruvate dehydrogenase, 2-ketoglutarate dehy- chair bound. She had rotatory nystagmus, optic atrophy and profound drogenase, and the branched chain ketoacid dehydrogenase, as well as hearing loss.
    [Show full text]
  • An Alternative Role of Fof1-ATP Synthase in Escherichia Coli
    An alternative role of FoF1-ATP synthase in Escherichia coli: synthesis of thiamine SUBJECT AREAS: BIOCHEMISTRY triphosphate ENZYMES Tiziana Gigliobianco1, Marjorie Gangolf1, Bernard Lakaye1, Bastien Pirson1, Christoph von Ballmoos2, CELL BIOLOGY Pierre Wins1 & Lucien Bettendorff1 CELLULAR MICROBIOLOGY 1Unit of Bioenergetics and cerebral Excitability, GIGA-Neurosciences, University of Lie`ge, B-4000 Lie`ge, Belgium, 2Department of Received Biochemistry and Biophysics, Arrhenius Laboratories for Natural Sciences, Stockholm University, SE-106 91 Stockholm, Sweden. 23 November 2012 Accepted In E. coli, thiamine triphosphate (ThTP), a putative signaling molecule, transiently accumulates in response 21 December 2012 to amino acid starvation. This accumulation requires the presence of an energy substrate yielding pyruvate. Published Here we show that in intact bacteria ThTP is synthesized from free thiamine diphosphate (ThDP) and Pi, the reaction being energized by the proton-motive force (Dp) generated by the respiratory chain. ThTP 15 January 2013 production is suppressed in strains carrying mutations in F1 or a deletion of the atp operon. Transformation with a plasmid encoding the whole atp operon fully restored ThTP production, highlighting the requirement for FoF1-ATP synthase in ThTP synthesis. Our results show that, under specific conditions of Correspondence and nutritional downshift, FoF1-ATP synthase catalyzes the synthesis of ThTP, rather than ATP, through a requests for materials highly regulated process requiring pyruvate oxidation. Moreover, this chemiosmotic mechanism for ThTP production is conserved from E. coli to mammalian brain mitochondria. should be addressed to L.B. (L.Bettendorff@ulg. ac.be) hiamine (vitamin B1) is an essential compound for all known life forms. In most organisms, the well-known cofactor thiamine diphosphate (ThDP) is the major thiamine compound.
    [Show full text]
  • CENTOGENE's Severe and Early Onset Disorder Gene List
    CENTOGENE’s severe and early onset disorder gene list USED IN PRENATAL WES ANALYSIS AND IDENTIFICATION OF “PATHOGENIC” AND “LIKELY PATHOGENIC” CENTOMD® VARIANTS IN NGS PRODUCTS The following gene list shows all genes assessed in prenatal WES tests or analysed for P/LP CentoMD® variants in NGS products after April 1st, 2020. For searching a single gene coverage, just use the search on www.centoportal.com AAAS, AARS1, AARS2, ABAT, ABCA12, ABCA3, ABCB11, ABCB4, ABCB7, ABCC6, ABCC8, ABCC9, ABCD1, ABCD4, ABHD12, ABHD5, ACACA, ACAD9, ACADM, ACADS, ACADVL, ACAN, ACAT1, ACE, ACO2, ACOX1, ACP5, ACSL4, ACTA1, ACTA2, ACTB, ACTG1, ACTL6B, ACTN2, ACVR2B, ACVRL1, ACY1, ADA, ADAM17, ADAMTS2, ADAMTSL2, ADAR, ADARB1, ADAT3, ADCY5, ADGRG1, ADGRG6, ADGRV1, ADK, ADNP, ADPRHL2, ADSL, AFF2, AFG3L2, AGA, AGK, AGL, AGPAT2, AGPS, AGRN, AGT, AGTPBP1, AGTR1, AGXT, AHCY, AHDC1, AHI1, AIFM1, AIMP1, AIPL1, AIRE, AK2, AKR1D1, AKT1, AKT2, AKT3, ALAD, ALDH18A1, ALDH1A3, ALDH3A2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDOA, ALDOB, ALG1, ALG11, ALG12, ALG13, ALG14, ALG2, ALG3, ALG6, ALG8, ALG9, ALMS1, ALOX12B, ALPL, ALS2, ALX3, ALX4, AMACR, AMER1, AMN, AMPD1, AMPD2, AMT, ANK2, ANK3, ANKH, ANKRD11, ANKS6, ANO10, ANO5, ANOS1, ANTXR1, ANTXR2, AP1B1, AP1S1, AP1S2, AP3B1, AP3B2, AP4B1, AP4E1, AP4M1, AP4S1, APC2, APTX, AR, ARCN1, ARFGEF2, ARG1, ARHGAP31, ARHGDIA, ARHGEF9, ARID1A, ARID1B, ARID2, ARL13B, ARL3, ARL6, ARL6IP1, ARMC4, ARMC9, ARSA, ARSB, ARSL, ARV1, ARX, ASAH1, ASCC1, ASH1L, ASL, ASNS, ASPA, ASPH, ASPM, ASS1, ASXL1, ASXL2, ASXL3, ATAD3A, ATCAY, ATIC, ATL1, ATM, ATOH7,
    [Show full text]
  • The Mitotic Checkpoint Is a Targetable Vulnerability of Carboplatin-Resistant
    www.nature.com/scientificreports OPEN The mitotic checkpoint is a targetable vulnerability of carboplatin‑resistant triple negative breast cancers Stijn Moens1,2, Peihua Zhao1,2, Maria Francesca Baietti1,2, Oliviero Marinelli2,3, Delphi Van Haver4,5,6, Francis Impens4,5,6, Giuseppe Floris7,8, Elisabetta Marangoni9, Patrick Neven2,10, Daniela Annibali2,11,13, Anna A. Sablina1,2,13 & Frédéric Amant2,10,12,13* Triple‑negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking efective therapy. Many TNBCs show remarkable response to carboplatin‑based chemotherapy, but often develop resistance over time. With increasing use of carboplatin in the clinic, there is a pressing need to identify vulnerabilities of carboplatin‑resistant tumors. In this study, we generated carboplatin‑resistant TNBC MDA‑MB‑468 cell line and patient derived TNBC xenograft models. Mass spectrometry‑based proteome profling demonstrated that carboplatin resistance in TNBC is linked to drastic metabolism rewiring and upregulation of anti‑oxidative response that supports cell replication by maintaining low levels of DNA damage in the presence of carboplatin. Carboplatin‑ resistant cells also exhibited dysregulation of the mitotic checkpoint. A kinome shRNA screen revealed that carboplatin‑resistant cells are vulnerable to the depletion of the mitotic checkpoint regulators, whereas the checkpoint kinases CHEK1 and WEE1 are indispensable for the survival of carboplatin‑ resistant cells in the presence of carboplatin. We confrmed that pharmacological inhibition of CHEK1 by prexasertib in the presence of carboplatin is well tolerated by mice and suppresses the growth of carboplatin‑resistant TNBC xenografts. Thus, abrogation of the mitotic checkpoint by CHEK1 inhibition re‑sensitizes carboplatin‑resistant TNBCs to carboplatin and represents a potential strategy for the treatment of carboplatin‑resistant TNBCs.
    [Show full text]
  • A Suppressor of a Centromere DNA Mutation Encodes a Putative Protein Kinase (MCK1)
    Downloaded from genesdev.cshlp.org on October 7, 2021 - Published by Cold Spring Harbor Laboratory Press A suppressor of a centromere DNA mutation encodes a putative protein kinase (MCK1) James H. Shero 1 and Philip Hieter Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 USA A new approach to identify genes involved in Saccharomyces cerevisiae kinetochore function is discussed. A genetic screen was designed to recover extragenic dosage suppressors of a CEN DNA mutation. This method identified two suppressors, designated MCK1 and CMS2. Increased dosage of MCK1 specifically suppressed two similar CEN DNA mutations in CDEIII, but not comparably defective CEN DNA mutations in CDEI or CDEII. A strain containing a null allele of MCK1 was viable under standard growth conditions, had a cold-sensitive phenotype (conditional lethality at l l°C), and grew slowly on Benomyl {a microtubule-destabilizing drug). Furthermore, when grown at 18°C or in the presence of Benomyl, the null mutant exhibited a dramatic increase in the rate of mitotic chromosome loss. The allele-specific suppression and chromosome instability phenotypes suggest that MCK1 plays a role in mitotic chromosome segregation specific to CDEIII function. The MCK1 gene encodes a putative protein-serine/threonine kinase, which suggests a possible role for the MCK1 protein in regulating the activity of centromere-binding proteins by phosphorylation. MCK1 was identified and cloned independently for its involvement in the induction of meiosis and is identical to a gene that encodes a phosphotyrosyl protein with protein kinase activity. [Key Words: S. cerevisiae; kinetochore function; CEN DNA; allele-specific suppression] Received December 12, 1990; revised version accepted January 28, 1991.
    [Show full text]
  • Perkinelmer Genomics to Request the Saliva Swab Collection Kit for Patients That Cannot Provide a Blood Sample As Whole Blood Is the Preferred Sample
    Autism and Intellectual Disability TRIO Panel Test Code TR002 Test Summary This test analyzes 2429 genes that have been associated with Autism and Intellectual Disability and/or disorders associated with Autism and Intellectual Disability with the analysis being performed as a TRIO Turn-Around-Time (TAT)* 3 - 5 weeks Acceptable Sample Types Whole Blood (EDTA) (Preferred sample type) DNA, Isolated Dried Blood Spots Saliva Acceptable Billing Types Self (patient) Payment Institutional Billing Commercial Insurance Indications for Testing Comprehensive test for patients with intellectual disability or global developmental delays (Moeschler et al 2014 PMID: 25157020). Comprehensive test for individuals with multiple congenital anomalies (Miller et al. 2010 PMID 20466091). Patients with autism/autism spectrum disorders (ASDs). Suspected autosomal recessive condition due to close familial relations Previously negative karyotyping and/or chromosomal microarray results. Test Description This panel analyzes 2429 genes that have been associated with Autism and ID and/or disorders associated with Autism and ID. Both sequencing and deletion/duplication (CNV) analysis will be performed on the coding regions of all genes included (unless otherwise marked). All analysis is performed utilizing Next Generation Sequencing (NGS) technology. CNV analysis is designed to detect the majority of deletions and duplications of three exons or greater in size. Smaller CNV events may also be detected and reported, but additional follow-up testing is recommended if a smaller CNV is suspected. All variants are classified according to ACMG guidelines. Condition Description Autism Spectrum Disorder (ASD) refers to a group of developmental disabilities that are typically associated with challenges of varying severity in the areas of social interaction, communication, and repetitive/restricted behaviors.
    [Show full text]
  • Adenosine Thiamine Triphosphate Accumulates In
    Gigliobianco et al. BMC Microbiology 2010, 10:148 http://www.biomedcentral.com/1471-2180/10/148 RESEARCH ARTICLE Open Access AdenosineResearch article thiamine triphosphate accumulates in Escherichia coli cells in response to specific conditions of metabolic stress Tiziana Gigliobianco1, Bernard Lakaye1, Pierre Wins1, Benaïssa El Moualij2, Willy Zorzi2 and Lucien Bettendorff*1 Abstract Background: E. coli cells are rich in thiamine, most of it in the form of the cofactor thiamine diphosphate (ThDP). Free ThDP is the precursor for two triphosphorylated derivatives, thiamine triphosphate (ThTP) and the newly discovered adenosine thiamine triphosphate (AThTP). While, ThTP accumulation requires oxidation of a carbon source, AThTP slowly accumulates in response to carbon starvation, reaching ~15% of total thiamine. Here, we address the question whether AThTP accumulation in E. coli is triggered by the absence of a carbon source in the medium, the resulting drop in energy charge or other forms of metabolic stress. Results: In minimal M9 medium, E. coli cells produce AThTP not only when energy substrates are lacking but also when their metabolization is inhibited. Thus AThTP accumulates in the presence of glucose, when glycolysis is blocked by iodoacetate, or in the presence lactate, when respiration is blocked by cyanide or anoxia. In both cases, ATP synthesis is impaired, but AThTP accumulation does not appear to be a direct consequence of reduced ATP levels. Indeed, in the CV2 E. coli strain (containing a thermolabile adenylate kinase), the ATP content is very low at 37°C, even in the presence of metabolizable substrates (glucose or lactate) and under these conditions, the cells produce ThTP but not AThTP.
    [Show full text]